 Home > Active Ingredient News > Drugs Articles > A collection of the latest trends and future plans for the JPM conference review of health care companies

A collection of the latest trends and future plans for the JPM conference review of health care companies

 Last Update: 2022-02-20
 Source: Internet
 Author: User

Tags

difference dna polymerase 1 3

test blood type

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

A few days ago, the 2022 JPM conference was successfully held online and ended successfully.
Many companies in the healthcare field announced their future plans.
This article summarizes the important information announced by the participating companies, in order to sort out the development trend of the healthcare field in 2022 for readers
.

1.
Illumina: Continue to maintain rapid growth in genomics and early cancer screening

Illumina CEO Francis deSouza said the accelerating adoption of genomics in healthcare drove the DNA sequencing company's revenue to approximately $4.
517 billion, up 39% from the previous year, and 2021 product shipments set a company record Highest record
.

But the company isn't planning to slow down, and expects to grow another 15% in 2022, helped by a slew of new products and partnerships -- including Grail's multi-cancer early-detection blood test, as well as adding long reads in the future Sequencing function to its current short read machine

Product shipments in 2021 are the highest in company history

2.
Johnson & Johnson: Partnering with Microsoft to help build a software ecosystem around its digital surgery efforts, 2022 leans toward small and mid-sized deals

Johnson & Johnson has partnered with Microsoft to build a cloud-connected software ecosystem around its digital surgery efforts—including apps designed to prepare patients for surgery, planning and navigation software, and robotic control software for performing surgery, as well as surgery.
post-rehabilitation program
.

Larry Jones, Chief Information Officer and Global Vice President, Medical Devices, Johnson & Johnson said: "Partnering with Microsoft will help us take our digitization to the next level as we create a best-in-class unified platform for innovative surgical technology
.

" In addition to patient-facing products, the platform will include workflow software for healthcare professionals

The project will also leverage Microsoft's Azure services, including artificial intelligence and machine learning, as well as edge computing and IoT support for medical devices located in operating rooms
.

After shrinking its portfolio in recent years and spinning off its consumer health business, Johnson & Johnson will once again turn to an acquirer role, making small deals for its medtech unit, Joaquin Duato, Johnson & Johnson's new chief executive, said
.

"Identifying products that complement our portfolio or allow us to enter high-growth segments -- that's what we're focusing on right now, " Mr.

Johnson & Johnson will once again turn to the acquirer role, making small deals for its medtech unit

We prefer small transactions, medium transactions,

3.
Medtronic: Invested $925 million to acquire Affera, a heart ablation technology company

At the JPM conference, Medtronic announced that it would acquire Affera, a medical technology company
.

Affera is a company that designs and develops cardiac mapping and navigation systems, as well as catheter-based cardiac ablation technologies, including differentiated focal pulsed field ablation solutions for the treatment of patients with cardiac arrhythmias, such as atrial fibrillation (AF)

Affera is a company that designs and develops cardiac mapping and navigation systems, as well as catheter-based cardiac ablation technologies.

4.
Exact Sciences: $190 million to acquire testing lab PreventionGenetics, sign license agreement with OncXerna Therapeutics

Exact Sciences announced the acquisition of testing lab PreventionGenetics for $190 million, aiming to expand its diagnostics franchise into hereditary cancer screening
.

PreventionGenetics offers more than 5,000 DNA tests, including germline and whole-exome sequencing chips, to help users understand their potential genetic risk for cancer or other diseases

More than 5,000 DNA tests are available, including germline and whole-exome sequencing chips, to help users understand their potential genetic risk for cancer or other diseases

Separately, Exact Sciences said it has signed a licensing agreement with OncXerna Therapeutics to bring the precision medicine company's tumor microenvironment testing program under its umbrella
.

OncXerna's Xerna test is designed to use RNA-based gene expression data to identify patients most likely to respond to certain immunotherapies, and has been used in drug development efforts before
.

It will first be available as part of Exact Sciences' GEM ExTra tumor sequencing test, which the company said plans to develop Xerna as a companion diagnostic in the future
.

OncXerna's Xerna test, designed to use RNA-based gene expression data to identify patients most likely to respond to certain immunotherapies, will initially be available as part of Exact Sciences' GEM ExTra tumor sequencing test,

5.
Dexcom: Announced the clinical trial data of the next-generation continuous glucose monitoring sensor (CGM), which has a high accuracy in measuring blood glucose values

Dexcom presented new data at JPM on its next-generation continuous glucose monitoring sensor (CGM), details from a large clinical study, and the device is currently awaiting U.
S.
FDA approval
.

The device is currently awaiting FDA approval
.

▲Dexcom's product portfolio (Image source: Fierce Biotech)

After recruiting more than 300 trial participants and comparing data from more than 39,000 individual readings paired with self-measured blood sugar levels, blood sugar values measured with the Dexcom G7 sensor fell within ± 93% of the reference blood sugar reading.
within the 20% range , including during periods of hyperglycemia, hypoglycemia, and normoglycemia
.

Blood glucose values measured with the Dexcom G7 sensor fell within ±20% of the reference blood glucose reading approximately 93% of the time

According to Mr.
Kevin Sayer, CEO of Dexcom, this is "very well in line" with the US FDA's standards for interoperable CGM devices
.
In addition, the mean absolute relative difference for the new system (or the overall difference rate when comparing the G7 system to a reference blood glucose value) was 8.
1% in pediatric users and 8.
2% in adults
.

The disposable G7 sensor is also 60 percent smaller than its predecessor, which debuted in 2018, and offers a 30-minute warm-up period after application
.

6.
Thermo Fisher: Mergers and acquisitions in 2021

Thermo Fisher's most high-profile move in 2021 is its $17.
4 billion acquisition of PPD
.
In an investor presentation by the company's CEO , Mr.
Marc Casper , the move into clinical research services was described as a "natural extension" of Thermo Fisher's service to biopharmaceutical clients
.
As the business integration progresses, Mr.
Casper said the company is now ready to support drugmakers "from the inception of a scientific idea all the way to an approved drug" by equipping research labs, assisting with research and providing manufacturing hardware
.

Mr.
Marc Casper

Mr.
Casper said Thermo Fisher spent a total of $24 billion on mergers and acquisitions in 2021, covering international viral vector manufacturers, cell sorter developers and rapid PCR test manufacturers
.
Most recently, the company acquired PeproTech , which makes the raw materials needed for cell and gene therapies, for $1.
85 billion .

.
Acquired PeproTech for $1.
85 billion

7.
Freenome: Received $290 million in strategic investment from Roche to expand early detection of cancer

Less than a month after the completion of the $300 million Series D financing, Freenome announced on January 11 that it had received a strategic investment of $290 million from Roche
.
Freenome CEO Mike Nolan revealed during the JPM conference that Freenome has raised more than $1.
1 billion in funding since its inception in 2014, of which about $350 million came from Roche
.

Freenome announced a $290 million strategic investment from Roche
.

Proceeds from the financing will help Freenome expand the scope of its multi-omics technology, developing new tests to detect a range of cancer types and, in some cases, multiple cancers simultaneously
.
Some of these multi-cancer tests will begin clinical studies in February
.

Freenome's multi-omics platform performs genomic, transcriptomic, methylome and proteomic analysis to find signs of cancer in standard blood draws
.
Freenome's first test, designed to detect colorectal cancer and advanced adenomas, is currently in clinical testing, and the PREEMPT CRC trial has now closed its registration period
.

Freenome's first test, designed to detect colorectal cancer and advanced adenomas, is currently in clinical testing, and the PREEMPT CRC trial has now closed its registration period
.

Machine learning-driven technology aims to detect cancer early, before it spreads throughout the body
.
Currently, about 53,000 Americans die each year from colorectal cancer, but when detected early and still localized, it has a 90 percent survival rate compared to just 14 percent after metastasis
.

But when detected early and still localized, it has a 90% survival rate, compared to just 14% after metastasis
.

In addition to developing new tests for the platform, Freenome is also focusing on making these tests widely available to every patient, and to that end includes broadly representative population samples in its clinical studies
.

8.
Quidel: Expanding capacity to meet diagnostic demand

Since announcing in early 2021 that it plans to open a 128,000-square-foot facility in California for mass production of rapid antigen diagnostics, Quidel said it expects to reach its manufacturing capacity goal of 70 million tests per month by mid-February
.

It expects to reach its manufacturing capacity goal of 70 million tests per month by mid-February
.

Currently, Quidel is working to complete the $6 billion acquisition of Ortho Clinical Diagnostics and is preparing to finally launch its new Savanna diagnostic system after years of development
.
The Savanna analyzer, which received CE certification last year for small and mid-sized hospitals, offers room temperature reagent, swab and liquid sample compatibility, results in approximately 25 minutes per run, and multiplex PCR capability that can test 12 different targets
.

9.
Roche: Launches new smartphone-like instant blood glucose monitor with professional diabetes management software

Roche has launched cobas Pulse, a new instant blood glucose monitor designed for hospital professionals, with a companion device shaped like a touchscreen smartphone that runs its own app
.

▲ Instant blood glucose monitor cobas Pulse (Image source: Fierce Biotech)

Roche said at the JPM conference that cobas Pulse will begin shipping to selected countries in Europe and plans to seek licenses in the U.
S.
and other markets within this year
.

Roche specifically hired diabetes cloud provider Glytec to provide the Glucommander insulin delivery program for its device to help simplify the complex task of managing blood sugar levels during a patient's hospital stay
.

The handheld cobas Pulse includes an automatic glucose test strip reader as well as a camera and touchscreen for recording other diagnostics, all embedded in a hardened body that can be cleaned with disinfectant
.
It is intended for use on patients of all ages, including neonatal and intensive care patients
.

The hand-held cobas Pulse includes an automatic glucose test strip reader as well as a camera and touch screen for recording other diagnostic results,

Glytec's Glucommander was first approved by the US FDA in 2006 and has since become a central part of the company's eGlycemic management system, a medical decision support program for insulin titration
.
It includes modules for hospitalized patients receiving nutrition through a feeding tube, and can recommend doses of various insulins, either intravenously or subcutaneously
.
According to Glytec, the software has been shown to reduce episodes of severe hypoglycemia by 99.
8 percent, while reducing readmission rates and length of stay
.

The software has been shown to reduce episodes of severe hypoglycemia by 99.
8%, while reducing readmission rates and length of stay
.

cobas Pulse is designed to simplify the clinician's workflow by running the Glucommander dosing software on the blood glucose meter itself - as well as decision support applications downloaded by other companies, including Smart4Diagnostics, imito, decision, CardioSignal and SteadySense
.

10.
Pacific Biosciences: Cooperate with Google to improve the accuracy of DNA sequencing products; cooperate with Chinese companies to develop small desktop sequencing systems

Pacific Biosciences will collaborate with machine learning researchers at Google to improve the accuracy of its DNA sequencing hardware
.

This isn't the first collaboration between the two companies
.
Research pre-published last year showed that Google's artificial intelligence tool could increase the yield of PacBio's long-read sequencing by 27 percent, and in some cases it had already reached 99.
9 percent
.

Pre-published research shows that Google's artificial intelligence tool can increase the yield of PacBio's long-read sequencing by 27%, which has already reached 99.
9% in some cases
.

The collaboration plans to integrate Google's deep learning technology into PacBio's future products, specifically aimed at improving the hardware's capabilities in whole-genome and targeted sequencing applications
.

"The more we can improve this accuracy, the more we can reduce costs, increase yields and help our customers solve important biological questions," said Mr.
Christian Henry, President and CEO of PacBio
.

Meanwhile, at the conference, PacBio announced a pilot project with Genomics England that uses the company's HiFi technology to sequence biobanks from patients with rare diseases
.

The collaboration will use the 100,000 Genomes Project to reanalyze samples whose DNA was previously read by short-read sequencers to see if PacBio's long-read machines can gain a clearer picture of a patient's genome and identify any other clinically relevant mutations
.

PacBio also announced an agreement with Chinese company Berry Genetics to develop its first small-scale benchtop sequencing system for the Chinese clinical market
.
Berry Genetics previously supported PacBio's Sequel II instrument in obtaining authorization from China's National Medical Products Administration (NMPA) in 2019
.

PacBio also announced an agreement with Chinese company Berry Genetics to develop its first small-scale benchtop sequencing system for the Chinese clinical market
.

11.
Renalytix: Assessment of kidney health, KidneyIntelX is expected to be approved by the US FDA this year

After laying the groundwork for the full rollout of KidneyIntelX technology over the past few years, Renalytix predicts that 2022 will be a milestone year, with the company's KidneyIntelX system expected to be approved by the U.
S.
FDA this year
.

Renalytix predicts that 2022 will be a milestone year, with the company's KidneyIntelX system expected to be approved by the U.
S.
FDA this year
.

KidneyIntelX is an artificial intelligence-driven tool that uses machine learning algorithms to analyze three blood-based biomarkers and seven data points extracted from electronic health records
.
The generated report provides a broad overview of a patient's kidney health, generating a score for the patient's individual risk of kidney disease progression or kidney failure
.

KidneyIntelX is an artificial intelligence-driven tool that uses machine learning algorithms to analyze three blood-based biomarkers and seven data points extracted from electronic health records
.

So far, the platform has primarily been used to diagnose rapidly progressive kidney disease in patients with type 2 diabetes
.
However, in a study published earlier, KidneyIntelX also showed promise in monitoring their response to various treatments for diabetic kidney disease
.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.